Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia.
A long-term assessment of quantitative hepatitis C virus (HCV) testing was performed at the University of Pittsburgh Medical Center. The Quantiplex HCV RNA 2.0 branched-chain DNA (bDNA) assay (Bayer Diagnostics) for hepatitis C viral load determination was used to test 3,471 specimens. bDNA-negative samples were also tested by an in-house qualitative reverse transcriptase (RT)-PCR assay with a measured sensitivity of fewer than 100 HCV genome equivalents per milliliter. Of 1,239 bDNA-negative specimens, 74.1% were negative and 25.9% were positive by RT-PCR, indicating the presence of viremia in a significant proportion of bDNA-negative samples. We discuss the medical and economic implications of these results and propose two alternatives for clinical laboratories to consider in approaching quantitative HCV testing. For laboratories able to perform a sensitive RT-PCR assay for </=40% of the bDNA test cost, prescreening bDNA requests by RT-PCR may be the most cost-effective approach.
Hofgärtner
W T
WT
Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213-2500, USA.
Kant
J A
JA
Weck
K E
KE
D004279:DNA, Viral / Q000032:analysis / Q000097:blood / Q000235:genetics; D005069:Evaluation Studies as Topic; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000821:virology*; D006801:Humans; D012367:RNA, Viral / Q000032:analysis / Q000097:blood* / Q000235:genetics; D011933:Reagent Kits, Diagnostic / Q000191:economics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019562:Viral Load
D004279:DNA, Viral; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic